



QSAR STUDY OF INDOLYLPYRIMIDINES DERIVATIVES AS ANTIBACTERIAL ACTIVITY

¹ Priyanka Dahiya ¹, Shailja sachan ², Sukhendra singh patel ³

¹Department of Chemistry 1st, A.P.S. University, Rewa (M.P.), INDIA – 486001

¹Department of Chemistry 1st, M. S. Golwalkar College, Rewa (M.P.), INDIA – 486001

Abstract: QSAR analysis on a set of indolympyrimidine derivatives compounds for (PA) antibacterial activity was performed by using multiple regression procedure. The activity contributions of these compounds were determined from regression equation and the validation procedure to analyze the predictive ability of QSAR model was described. The best QSAR model with good correlation coefficient ($r^2=0.8360$), Q-ratio= 0.341, F-ratio =30.593 and N = 22. The leave-one-out (LOO) cross validation method using Ridge regression analysis was used in the future to confirm this model.

Keywords - QSAR analysis, Inhibitory Activity, QSAR, LOO.

I. INTRODUCTION

An important contributor to hospital acquired infections and antimicrobial resistance is gram-negative bacterium *Pseudomonas aeruginosa* (PA).^[1,2] *Pseudomonas aeruginosa* is in charge of a variety of infectious cases, including nosocomial pneumonia, urinary tract infections, surgical wound infections, and bloodstream infections.^[3] Gram-positive and gram-negative bacteria have different cell walls in terms of structure. Antibiotics side effects, digestive enzymes, reactions, and heavy metal toxicity are all protected from by the outer membrane. Many chemical substances function as antibacterial agents by preventing the DNA synthesis of cell wall by blocking enzymes like DNA gyrase and dihydrofolate reductase and even by inhibiting enzymes processing the growth of peptidoglycan layer.^[4,5] In the current work, we have made an effort to use QSAR molecular descriptors, which explains surface phenomenon, to distinguish between how chemical entities behave towards gram positive and gram negative bacteria. The goal of the current study was to examine the utility of QSAR in the anticipation of indolympyrimidine derivatives antibacterial activity against *Pseudomonas aeruginosa* (PA) and *Staphylococcus aureus* (SA). Learn how multiple linear regression (MLR) equations can be used to describe the correlation between the distinct behavior of activity against both gram positive and gram negative strains. Multiple downstream signaling cascades are recruited, phosphorylated, and activated as a result of this metabolic activity. Numerous cancers, including non-small cell lung cancer (NSCLC), osteosarcoma, breast cancer, acute myeloid leukemia, prostate cancer, and colorectal cancer, have been found to overexpress AXL.^[6] Pyrimidine compounds are important in medicine because they work well as analgesic, the release of anti-inflammatory mediators such as histamine from mast cell, which are responsible for inflammatory and hypotension.^[7] Anticonvulsant, insecticidal, herbicidal, antitubercular, anti-cancer and antidiabetic agents. The indole ring is recognized to have anti-inflammatory, antimicrobial and antifungal activities.^[8-12] The fused ring system of substituted indolympyrimidines is remarkably effective as antitumor and antibacterial activity.^[13,14] The chemical structures were designed using ACD/ChemSketch 2021 and were saved as mol. files. The Dragon program was used to calculate the values of 28 descriptors shown.^[15, 16]

11. BIOLOGICAL ACTIVITIES

In a series of indolympyrimidines-based selective *Pseudomonas aeruginosa* (PA) and *Staphylococcus aureus* (SA) derivatives tests, each compound was examined for its ability to inhibit the growth of bacteria. The results are presented in the form of *Pseudomonas aeruginosa* (PA antibact), which was first established as converted to the 100 µg/mL and distance unit, value, millimeters (mm). This is directly collected from the work and used as the dependent variable in the QSAR study Panda and coworker's.^[17-21]

11.1. RESULTS AND DISCUSSION

In order to understand the experimental biological activity data of 28 indolylpyrimidines derivatives antibacterial activity as selective *Pseudomonas aeruginosa*, regression equation the most significant in contribution to inhibitory activity, we established a QSAR study between their in antibacterial activity and descriptors coding for molecular descriptors; Burden eigenvalues SpMax5_Bh(e), and SpMin7_Bh(i), Information(Yindex), Topological(DECC), Constitutional(MW), Edge(SpAD_EA(bo), Eta (Eta_betaS), descriptors of the molecules under consideration using Hansch and Fujita.^[22-23] Pearson's correlation matrix has been performed on all descriptors by using NCCS statistical Software.^[24] The analysis of the matrix revealed six descriptors for the development of MLR model. The value of descriptors selected for MLR model are presented in Table 3 the correlation coefficient from 0.8360. The QSAR equation is supposed to be good if the *F*-test is above a threshold value. The statistical quality of the resulting models, as depicted in Table 6, is determined by *r*, standard error (std error), and randomization test. (ran *r*²)^[25-26]

Table 1: Structure and Activity of compounds

| Com. no | R1 | R2 | <i>Pseudomonas aeruginosa</i> (PA) Antibacteria |
|---------|-----------------|--------------------|---|
| 1 | OH | H | 13 |
| 2 | OH | p-NH ₂ | 24 |
| 3 | OH | p-Br | 19 |
| 4 | OH | P-Cl | 18 |
| 5 | OH | O,p-OH | 14 |
| 6 | OH | P-F | 17 |
| 7 | OH | P-CH ₃ | 13 |
| 8 | OH | P-OCH ₃ | 17 |
| 9 | OH | p-OH | 11 |
| 10 | OH | p-NO ₂ | 23 |
| 11 | SH | H | 12 |
| 12 | SH | p-NH ₂ | 18 |
| 13 | SH | p-Br | 15 |
| 14 | SH | P-Cl | 16 |
| 15 | SH | P-F | 14 |
| 16 | SH | P-CH ₃ | 10 |
| 17 | SH | P-OCH ₃ | 13 |
| 18 | SH | p-NO ₂ | 19 |
| 19 | NH ₂ | H | 11 |
| 20 | NH ₂ | p-NH ₂ | 10 |
| 21 | NH ₂ | p-Br | 17 |
| 22 | NH ₂ | P-Cl | 15 |
| 23 | NH ₂ | O,p-OH | 13 |
| 24 | NH ₂ | P-F | 23 |
| 25 | NH ₂ | P-CH ₃ | 13 |
| 26 | NH ₂ | P-OCH ₃ | 25 |
| 27 | NH ₂ | p-OH | 13 |
| 28 | NH ₂ | p-NO ₂ | 24 |

Detailed Name of Descriptors

| Name of Descriptors | Detailed Name of Descriptors |
|---------------------|--|
| MW | molecular weight |
| Y index EA | Balaban Y index |
| DECC | Eccentric |
| SpMax5_Bh(e) | largest eigenvalue n. 5 of Burden matrix weighted by Sanderson electronegativity |
| SpMin7_Bh(i) | smallest eigenvalue n. 7 of Burden matrix weighted by ionization potential |
| SpAD_EA(bo) | spectral absolute deviation from edge adjacency mat. weighted by bond order |
| Eta_betaS | eta sigma VEM count |

Table.2 Descriptor used in QSAR study

| PA | Y index | DECC | MW | SpMax5_Bh(e) | SpMin7_Bh(i) | SpAD_EA(bo) | Eta_betaS |
|----|---------|-------|--------|--------------|--------------|-------------|-----------|
| 13 | 0.645 | 1.227 | 276.23 | 2.828 | 0.346 | 50.284 | 14.25 |
| 24 | 0.617 | 1.365 | 289.23 | 2.842 | 0.345 | 52.034 | 15 |
| 19 | 0.617 | 1.365 | 355.12 | 2.843 | 0.349 | 52.034 | 14.75 |
| 18 | 0.617 | 1.365 | 310.67 | 2.85 | 0.347 | 52.034 | 15 |
| 14 | 0.624 | 1.347 | 307.22 | 2.895 | 0.425 | 53.722 | 15.75 |
| 17 | 0.617 | 1.365 | 294.22 | 2.867 | 0.341 | 52.034 | 15 |
| 13 | 0.617 | 1.365 | 287.23 | 2.832 | 0.35 | 52.034 | 14.75 |
| 17 | 0.586 | 1.469 | 303.23 | 2.902 | 0.367 | 53.322 | 15.75 |
| 11 | 0.617 | 1.365 | 291.22 | 2.855 | 0.346 | 52.034 | 15 |
| 23 | 0.566 | 1.52 | 321.23 | 3.021 | 0.511 | 57.789 | 16.5 |
| 12 | 0.645 | 1.227 | 292.3 | 2.813 | 0.362 | 50.284 | 14 |
| 18 | 0.617 | 1.365 | 305.3 | 2.828 | 0.36 | 52.034 | 14.75 |
| 15 | 0.617 | 1.365 | 371.19 | 2.829 | 0.365 | 52.034 | 14.5 |
| 16 | 0.617 | 1.365 | 326.74 | 2.836 | 0.363 | 52.034 | 14.75 |
| 14 | 0.617 | 1.365 | 310.29 | 2.853 | 0.355 | 52.034 | 14.75 |
| 10 | 0.617 | 1.365 | 303.3 | 2.817 | 0.367 | 52.034 | 14.5 |
| 13 | 0.586 | 1.469 | 319.3 | 2.889 | 0.384 | 53.322 | 15.5 |
| 19 | 0.566 | 1.52 | 337.3 | 3.016 | 0.532 | 57.789 | 16.25 |
| 11 | 0.645 | 1.227 | 274.24 | 2.818 | 0.342 | 50.284 | 14.25 |
| 10 | 0.617 | 1.365 | 287.24 | 2.832 | 0.341 | 52.034 | 15 |
| 17 | 0.617 | 1.365 | 353.13 | 2.833 | 0.345 | 52.034 | 14.75 |
| 15 | 0.617 | 1.365 | 308.68 | 2.84 | 0.343 | 52.034 | 15 |
| 13 | 0.624 | 1.347 | 305.23 | 2.888 | 0.423 | 53.722 | 15.75 |
| 23 | 0.617 | 1.365 | 292.23 | 2.857 | 0.337 | 52.034 | 15 |
| 13 | 0.617 | 1.365 | 285.24 | 2.821 | 0.346 | 52.034 | 14.75 |
| 25 | 0.586 | 1.469 | 301.24 | 2.893 | 0.362 | 53.322 | 15.75 |
| 13 | 0.617 | 1.365 | 289.23 | 2.845 | 0.342 | 52.034 | 15 |
| 24 | 0.566 | 1.52 | 319.24 | 3.017 | 0.505 | 57.789 | 16.5 |

Table 3 Correlation Matrix of different descriptors

| | PA | Y index | DECC | MW | SpMax5_Bh_e_ | SpMin7_Bh_i_ | SpAD_EA_bo_ | Eta_beta_S |
|--------------|---------|---------|--------|--------|--------------|--------------|-------------|------------|
| PA | 1.0000 | | | | | | | |
| Y_index | -0.5801 | 1.0000 | | | | | | |
| DECC | 0.5676 | -0.9832 | 1.0000 | | | | | |
| MW | 0.2711 | -0.3700 | 0.4006 | 1.0000 | | | | |
| SpMax5_Bh_e_ | 0.5441 | -0.8619 | 0.8002 | 0.2640 | 1.0000 | | | |
| SpMin7_Bh_i_ | 0.3632 | -0.7209 | 0.6488 | 0.3241 | 0.9226 | 1.0000 | | |
| SpAD_EA_bo_ | 0.5185 | -0.8931 | 0.8581 | 0.3546 | 0.9675 | 0.9345 | 1.0000 | |
| Eta_betaS | 0.5404 | -0.8661 | 0.8596 | 0.2093 | 0.9236 | 0.8030 | 0.9270 | 1.0000 |

Table 4 result of cross validation

| Model No | N | Press | SSY | Press/SSY | R ² | R ² cv | PSE | Spress |
|----------|----|---------|---------|-----------|----------------|-------------------|-------|--------|
| 1 | 28 | 356.834 | 181.023 | 1.971 | 0.336 | -0.971 | 0.674 | 3.704 |
| 2 | 28 | 309.000 | 228.857 | 1.351 | 0.425 | -0.351 | 0.627 | 3.515 |
| 3 | 28 | 284.128 | 253.728 | 1.119 | 0.471 | -0.119 | 0.602 | 3.441 |
| 4 | 22 | 48.265 | 246.097 | 0.196 | 0.836 | 0.803 | 0.315 | 1.637 |

Model No.1 PA = 90.1201 - 121.0509 Y_index [1]

N= 28, MSE= 13.724, R²= 0.336, AR²= 0.311, Q-VALUE= 0.042

Here N is the number of compounds used in the study, MSE is the mean square error of estimation, R² is the regression coefficient, AR² is the adjusted Regression coefficient, F-ratio and Q= R²/MSE; Pogliani's Quality factor.^[27]

The regression analysis gave many biparametric model follow rule of thumb. The QSAR Model NO.2 has significant.

Model No.2 PA = -259.4234+ 106.1352SpMax5_Bh_e_ - 76.6172SpMin7_Bh_i_ [2]

N= 14, MSE= 12.361, R²= 0.425, AR²= 0.379, Q-VALUE= 0.052

The QSAR model no. 1 and model no. 2 has significant importance in which SpMax5_Bh_e_ show positive contribution while Y_index and SpMin7_Bh_i_ show inverse concentration with inhibitory activity.

Model No.3 PA = -280.4490+ 110.1869SpMax5_Bh_e_ - 86.7643SpMin7_Bh_i_ + 0.04294MW [3]

N= 28, MSE= 11.838, R²= 0.471, AR²= 0.405, Q-VALUE= 0.057

Various triparametric model have been obtained with similar statistics, out of which one contain SpMax5_Bh_e_ ,SpMin7_Bh_i_ ,and MW was found to give good result the model obtained is as follows.

Finally in order to confirm which out of the proposed model is the most appropriated for modelling the inhibitory.

Model No.4 PA = -244.7347+ 92.6277SpMax5_Bh_e_ - 63.1236SpMin7_Bh_i_ + 0.0592 MW [4]

N= 22, MSE= 2.681, R²= 0.8360, AR²= 0.808, Q-VALUE= 0.341

We calculated the pogliani's quality factor Q which is Ratio of R and MSE means square error the these Q-value maximum value is found for, eq. 4 with the highest correlation coefficient (r = 0.9143) with R²cv = 0.803 was considered to be the best model.

IV. CONCLUSIONS



From the result and discussion made above, we conclude that the QSAR study of Indolylpyrimidines derivatives as antibacterial activity were more active against the gram-negative bacteria *Pseudomonas aeruginosa* agents. Linear regression for the total data set of 28 compounds in the present study with Indolylpyrimidines derivatives as antibacterial activity demonstrated that the SpMax5_Bh(e), SpMin7_Bh(i), (MW), molecular descriptors appears to be governing factors for the biological potency of QSAR Study of Indolylpyrimidines derivatives as antibacterial activity.

The following conclusions are obtained from this analysis.


1. The positive coefficient of SpMax5_Bh(e), MW, suggest that these parameters plays a dominating role in deciding the activity of present set of compounds.
2. The negative coefficient of SpMin7_Bh(i), suggest that the low or negative value of SpMin7_Bh(i), will favors the biological activity(Antibacterial).

Table 5: Observed and predicted activity

| Com no | Obs. | Predicted | |
|--------|------|-----------|----------|
| | PA | PA | Residual |
| 1 | 13 | 11.73766 | 1.26234 |
| 2 | 19 | 17.61057 | 1.389434 |
| 3 | 18 | 15.75232 | 2.247682 |
| 4 | 14 | 14.79257 | -0.79257 |
| 5 | 17 | 16.73136 | 0.268644 |
| 6 | 13 | 12.50723 | 0.492765 |
| 7 | 17 | 18.8658 | -1.8658 |
| 8 | 23 | 21.86488 | 1.135119 |
| 9 | 12 | 10.29013 | 1.709868 |
| 10 | 15 | 16.25566 | -1.25567 |
| 11 | 16 | 14.39742 | 1.602582 |
| 12 | 14 | 15.5027 | -1.5027 |
| 13 | 10 | 10.99658 | -0.99658 |
| 14 | 19 | 21.02801 | -2.02801 |
| 15 | 11 | 10.946 | 0.053996 |
| 16 | 10 | 13.07594 | -3.07594 |
| 17 | 17 | 16.81891 | 0.18109 |
| 18 | 15 | 14.96066 | 0.039338 |
| 19 | 13 | 14.15255 | -1.15255 |
| 20 | 13 | 11.62295 | 1.377049 |
| 21 | 13 | 14.33485 | -1.33485 |
| 22 | 24 | 21.75524 | 2.244761 |



Variance Inflation Factor Plot



II. ACKNOWLEDGMENT

We are thankful to Dr. V.K. Agrawal, for his valuable and inspiration for doing this work. One of the authors Dr. Shailja Sachan is particularly thankful to UGC Bhopal for financial support to purchase NCSS and E-dragon software used in this work, without which this would not have been possible.

REFERENCES

- [1] Nicoll L., 1995. "Pseudomonas aeruginosa: infections and treatment," New England Journal of Medicine, (332): 616–617.
- [2] Vila J. and Pal T., 2010. "Update on antibacterial resistance in low-income countries: factors favoring the emergence of resistance," Open Infectious Diseases Journal, 4(1): 38–54.
- [3] Van Delden C. and Iglewski B. H., 1998. "Cell-to-cell signaling and Pseudomonas aeruginosa infections," 4(4): 551–560.
- [4] Charifson P. S, Grossman T. H., and Mueller P., 2009. "The use of structure-guided design to discover new anti-microbial agents: focus on antibacterial resistance," Anti-Infective Agents in Medicinal Chemistry, 8(1):73–86.
- [5] Vila J., S´anchez-C´espedes J., and Giralt E., 2005. "Old and new strategies for the discovery of antibacterial agents," Current Medicinal Chemistry: Anti-Infective Agents, 4 (4): 337–353.
- [6] Dahiya P., QSAR Study of Pyrimidine Derivatives as AXL Kinase Inhibitors for their Anticancer Activity, International Journal of Pharmaceutical Research and Application, 8, 1, 365-373, (2023).
- [7] Patel S. S., QSAR Modeling of 1,2,4-Triazole [5,1-i] Purine Derivatives With Adenosine Receptor Subtype, International Journal of Pharmaceutical Research and Application, 8, 1, 374-381, (2023).
- [8] Patel H. D., Mistry B. D., and Desai K. R., 2003. "Synthesis and antimicrobial activity of pyrazolo [3,4-d] pyrimidines," Indian Journal of Heterocyclic Chemistry, 13(2):179–180.
- [9] Kreutzberger A. and Sellheim M., 1985. "Antimycotic agents. XIX. [1,2] 4,6-disubstituted 2-(cyanamino)pyrimidine derivatives," Journal of Heterocyclic Chemistry, 22,(3):721–723.
- [10] Lather V. and Chowdary P.V., 2003. "Synthesis and antimicrobial activity of N1-(arylidine hydrazidomethyl)-indoles, 2-(substitutedaryl)-3-(N1-indolyl acetamidyl)-4-oxo-thiazolidines and 5-benzylidene derivatives of thiazolidinones," Indian Journal of Pharmaceutical Sciences, 65(6): 576–579.
- [11] Gadaginamath G. S., Shyadligeri A. S., and Kavali R.R., 1999. "Chemoselectivity of indole-dicarboxylates towards hydrazine hydrate: part III-synthesis and antimicrobial activity of novel 4-thiazolidinonylindoles," Indian Journal of Chemistry B: Organic and Medicinal Chemistry, 38(2): 156–159.
- [12] Renukadevi P. and Biradar J. S, 1999. "Synthesis and antimicrobial activity of 3,5-disubstituted-2-[1'-phenyl-5'-thioalkyl-s-triazol-2'-yl]indoles and 3,5-disubstituted-2-[1'-substituted aminomethyl-4'-phenyl-5' (4'h)-thione-s-triazol-3-yl] indoles," Indian Journal of Heterocyclic Chemistry, 9 (2):107–112.
- [13] Jiang B., Yang C., Xiong W., and Wang J., 2001. "Synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents," Bioorganic and Medicinal Chemistry, 9(5): 1149–1154.
- [14] Radwan M.A.A. and El-Sherbiny M., 2007. "Synthesis and antitumor activity of indolylpyrimidines: marine natural product meridianin D analogues," Bioorganic and Medicinal Chemistry, 15 (3):1206–1211.
- [15] ACD-Labs software ChemSketch. www.acdlabs.com
- [16] Talete srl, DRAGON: Software. www.disat.unimib.it
- [17] Panda S. and Chowdary P. V. R, 2008. "Synthesis of novel indolylpyrimidine anti-inflammatory, antioxidant and antibacterial agents," Indian Journal of Pharmaceutical Sciences, 70(2):208–215.
- [18] Veber D. F., Johnson S. R., Cheng H., Smith B. R., Ward K. W., and Kopple K. D., 2002. "Molecular properties that influence the oral bioavailability of drug candidates," Journal of Medicinal Chemistry, 45(12):2615–2623.
- [19] Masuda T., Jikihara T., Nakamura K., Kimura A., Takagi T., and Fujiwara H., 1997. "Introduction of solvent-accessible surface area in the calculation of the hydrophobicity parameter log P from an atomistic approach," Journal of Pharmaceutical Sciences, 86(1): 57–63.
- [20] 2007. Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship [(Q)SAR] Models. OECD Environment Health and Safety Publications Series on Testing and Assessment No. 69. OECD: Paris, <http://www.oecd.org/dataoecd/55/35/38130292.pdf>.
- [21] Topliss J. G and Edwards R. P., 1979. "Chance factors in studies of quantitative structure-activity relationships," Journal of Medicinal Chemistry, 22(10):1238–1244.
- [22] Hansch, C., Fujita, T., 1964. J. Am. Chem. Soc., (86): 1616-1626.
- [23] Free, S.M. Wilson, J.W., 1964. J. Med. Chem., (7):395-399.
- [24] NCSS statistical software, www.ncss.com
- [25] Snedecor G.W. and Cochran W. G., 1967. Statistical Methods, Oxford and IBH, New Delhi, India.
- [26] Chatterjee S., Hadi A. S., and Price B., 2000. Regression Analysis by Examples, Wiley VCH, New York, NY, USA.
- [27] Pogliani L, 1996. Modeling with Special Descriptors Derived from a Medium-Sized Set of Connectivity Indices J. Phys. Chem.;(100): 18065-18077.